Wf-536 inhibits metastatic invasion by enhancing the host cell barrier and inhibiting tumour cell motility

Clinical and Experimental Pharmacology and Physiology

Volumn 30, Issue 7, 2003, Pages 457-463

  Nakajima, Masahide ^a   Katayama, Ken Ichi ^a   Tamechika, Ichiro ^a   Hayashi, Kazutaka ^a   Amano, Yusaku ^a   Uehata, Masayoshi ^a   Goto, Nobuharu ^a   Kondo, Takao ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Motility; Paracellular infiltration; Paracellular permeabiliy; Rho; Rho associated coiled coil forming protein serine threonine kinase; Tumor cells; Wf 536

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)BENZAMIDE MONOHYDROCHLORIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; BENZAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIDINE DERIVATIVE; RHO KINASE; RHO-ASSOCIATED KINASE; SCATTER FACTOR; UNCLASSIFIED DRUG; WF 536; Y 32885;

ARTICLE; BASEMENT MEMBRANE; CANCER INHIBITION; CANCER INVASION; CELL CULTURE; CELL FUNCTION; CELL INFILTRATION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL MOTILITY; CELL MOTION; CELL STRAIN; COCULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; FIBROSARCOMA; HUMAN; HUMAN CELL; METABOLISM; METASTASIS; METASTASIS INHIBITION; METHODOLOGY; PATHOLOGY; PERMEABILITY BARRIER; PHYSIOLOGY; TIGHT JUNCTION;

BASEMENT MEMBRANE; BENZAMIDES; CELL MOVEMENT; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM METASTASIS; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; TIGHT JUNCTIONS; TUMOR CELLS, CULTURED;

EID: 0038235310     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2003.03855.x     Document Type: Article

References (43)

1. Ridley AJ, Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992; 70: 389-99.
2. Nobes CD, Hall A. Rho, Rac and cdc42 GTPases. Regulators of actin structures, cell adhesion and motility. Biochem. Soc. Trans. 1995; 23: 456-9.
3. Narumiya S, Ishizaki T, Watanabe N. Rho effectors and reorganization of actin cytoskeleton. FEBS Lett. 1997; 410: 68-72.
4. Ishizaki T, Naito M, Fujisawa K et al. p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett. 1997; 404: 118-24.
5. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J. Biol. Chem. 1995; 270: 29 051-4.
6. Matsui T, Amano M, Yamamoto T et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996; 15: 2208-16.
7. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996; 392: 189-93.
8. Imamura F, Mukai M, Ayaki M, Akedo H. Y-27632, an inhibitor of Rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn. J. Cancer Res. 2000; 91: 811-16.
9. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem. Biophys. Res. Commun. 2000; 269: 652-9.
10. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat. Med. 1999; 5: 221-5.
11. Fujii A, Otsuki M, Kataoka H et al. Wf-536, a novel and potent inhibitor of Rho-associated protein kinase (ROCK): Inhibitory effects on lymph node and pulmonary metastasis of mouse B16F10 melanoma. Proc. Am. Assoc. Cancer Res. 2001; 42: 924 (Abstract).
12. Hayashi K, Amano Y, Katayama K et al. WF-536, a novel and potent inhibitor of Rho-associated protein kinase (ROCK): Inhibition of in vitro tumor cell invasion and spontaneous evolution of mouse tumor into metastasis. Proc. Am. Assoc. Cancer Res. 2001; 42: 924 (Abstract).
13. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327-36.
14. Nicolson GL. Molecular mechanisms of cancer metastasis: Tumor and host properties and the role of oncogenes and suppressor genes. Curr. Opin. Oncol. 1991; 3: 75-92.
15. Jiang WG, Martin TA, Llaffafian I, Mansel RE. Tight junctions, a critical structure in the control of cancer invasion and metastasis. In: Jiang WG, Mansel RE (eds). Cancer Metastasis: Molecule and Cellular Mechanisms and Clinical Intervention. Kluwer Academic, Amsterdam. 2000; Ch. 7.
16. Tsukita S, Furuse M, Itoh M. Molecular dissection of tight junctions. Cell Struct. Funct. 1996; 21: 381-5.
17. Morita K, Furuse M, Fujimoto K, Tsukita S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc. Natl Acad. Sci. USA 1999; 96: 511-16.
18. Yurchenco PD, Schittny JC. Molecular architecture of basement membranes. FASEB J. 1990; 4: 1577-90.
19. Ishizaki T, Uehata M, Tamechika I et al. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases. Mol. Pharmacol. 2000; 57: 976-83.
20. Adelstein RS, Klee CB. Purification of smooth muscle myosin light-chain kinase. Methods Enzymol. 1982; 85: 298-308.
21. Jiang WG, Martin TA, Matsumoto K, Nakamura T, Mansel RE. Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells. J. Cell. Physiol. 1999; 181: 319-29.
22. Hirase T, Kawashima S, Wong EY et al. Regulation of tight junction permeability and occludin phosphorylation by RhoA- p160ROCK-dependent and -independent mechanisms. J. Biol. Chem. 2001; 276: 10 423-31.
23. Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389: 990-4.
24. Manning Jr TJ, Parker JC, Sontheimer H. Role of lysophosphatidic acid and Rho in glioma cell motility. Cell Motil. Cytoskeleton 2000; 45: 185-99.
25. Nath D, Slocombe PM, Webster A, Stephens PE, Docherty AJ, Murphy G. Meltrin γ (ADAM-9) mediates cellular adhesion through α6β1 integrin, leading to a marked induction of fibroblast cell motility. J. Cell. Sci. 2000; 113: 2319-28.
26. Anderson JM, Balda MS, Fanning AS. The structure and regulation of tight junctions. Curr. Opin. Cell. Biol. 1993; 5: 772-8.
27. Satoh H, Zhong Y, Isomura H et al. Localization of 7H6 tight junction-associated antigen along the cell border of vascular endothelial cells correlates with paracellular barrier function against ions, large molecules, and cancer cells. Exp. Cell Res. 1996; 222: 269-74.
28. Jiang WG, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit. Rev. Oncol. Hematol. 1999; 29: 209-48.
29. Neufeld G, Kessler O, Vadasz Z, Gluzman-Poltorak Z. The contribution of proangiogenic factors to the progression of malignant disease: Role of vascular endothelial growth factor and its receptors. Surg. Oncol. Clin. North Am. 2001; 10: 339-56.
30. Carbajal JM, Gratrix ML, Yu CH, Schaeffer Jr RC. ROCK mediates thrombin's endothelial barrier dysfunction. Am. J. Physiol. 2000; 279: C195-204.
31. Essler M, Retzer M, Bauer M, Heemskerk JW, Aepfelbacher M, Siess W. Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. J. Biol. Chem. 1999; 274: 30 361-4.
32. Fujita H, Katoh H, Hasegawa H et al. Molecular decipherment of Rho effector pathways regulating tight-junction permeability. Biochem. J. 2000; 346: 617-22.
33. Rubin LL. Endothelial cells: Adhesion and tight junctions. Curr. Opin. Cell. Biol. 1992; 4: 830-3.
34. Schneeberger EE, Lynch RD. Structure, function, and regulation of cellular tight junctions. Am. J. Physiol. 1992; 262: L647-61.
35. Citi S. The molecular organization of tight junctions. J. Cell Biol. 1993; 121: 485-9.
36. Anderson JM, Van Itallie CM. Tight junctions and the molecular basis for regulation of paracellular permeability. Am. J. Physiol. 1995; 269: G467-75.
37. Lum H, Malik AB. Regulation of vascular endothelial barrier function. Am. J. Physiol. 1994; 267: L223-41.
38. Schnittler HJ, Wilke A, Gress T, Suttorp N, Drenckhahn D. Role of actin and myosin in the control of paracellular permeability in pig, rat and human vascular endothelium. J. Phsyiol. 1990; 431: 379-401.
39. Wysolmerski RB, Lagunoff D. Involvement of myosin light-chain kinase in endothelial cell retraction. Proc. Natl Acad. Sci. USA 1990; 87: 16-20.
40. Turner JR, Rill BK, Carlson SL et al. Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am. J. Physiol. 1997; 273: C1378-85.
41. Essler M, Amano M, Kruse HJ, Kaibuchi K, Weber PC, Aepfelbacher M. Thrombin inactivates myosin light chain phosphatase via Rho and its target Rho kinase in human endothelial cells. J. Biol. Chem. 1998; 273: 21 867-74.
42. Essler M, Hermann K, Amano M et al. Pasteurella multocida toxin increases endothelial permeability via Rho-kinase and myosin light chain phosphatase. J. Immunol. 1998; 161: 5640-6.
43. Albini A, Iwamoto Y, Kleinman HK et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987; 47: 3239-45.